Marvin Becker, MD
Internal Medicine · Bronx, NYNPI 1487661286
Payments from drug & device makers
Across 114 payments — averaging $31.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Mannkind Corporation$355
- AbbVie$319
- Dexcom, Inc.$273
- Johnson & Johnson$143
- GSK$112
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,578100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,270 |
| Mannkind Corporation | 3 | $355 |
| AbbVie | 17 | $319 |
| Dexcom, Inc. | 3 | $273 |
| Johnson & Johnson | 8 | $143 |
| GSK | 6 | $112 |
| AstraZeneca | 6 | $108 |
| Novartis | 5 | $106 |
| Amarin Pharma, Inc. | 5 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Novo Nordisk | 4 | $87 |
| Lilly USA, LLC | 5 | $74 |
| Merck | 4 | $59 |
| Amgen | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Nalpropion Pharmaceuticals LLC | 2 | $41 |
| Boehringer Ingelheim | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $35 |
| Boston Scientific | 1 | $34 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$315
- AFREZZA$264
- DEXCOM G6 TRANSMITTER$253
- COROFLOW$180
- Diamondback Coronary$170
- AVEIR$133
- GALLANT$125
- DRAGONFLY OPSTAR$121
- Ultreon$120
How this compares
$3,578 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $78,397 |
| EliquisApixaban | 68 | $77,068 |
| AfrezzaInsulin Regular, Human | 27 | $68,807 |
| JanuviaSitagliptin Phosphate | 60 | $65,722 |
| FarxigaDapagliflozin Propanediol | 36 | $51,057 |
| OzempicSemaglutide | 25 | $48,714 |
| Diclofenac Potassium | 17 | $32,378 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $21,987 |
| EntrestoSacubitril/Valsartan | 18 | $21,794 |
| TrulicityDulaglutide | 20 | $20,139 |
| Diclofenac Sodium | 40 | $14,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,689 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $10,699 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,454 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $74 | $98,53687 claims |
| MerckJanuvia, Janumet | $59 | $87,70974 claims |
| Mannkind CorporationAfrezza | $355 | $68,80727 claims |
| AstraZenecaFarxiga | $108 | $51,05736 claims |
| Novo NordiskOzempic | $87 | $48,71425 claims |
| NovartisEntresto | $106 | $21,79418 claims |
| GSKTrelegy Ellipta | $112 | $13,68914 claims |
| AbbVieSynthroid | $319 | $1,41413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.